Pular para o conteúdo
Merck
Todas as fotos(1)

Key Documents

Outros documentos

T0014000

Tamoxifen citrate

European Pharmacopoeia (EP) Reference Standard

Sinônimo(s):

Tamoxifen citrate salt, (Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C26H29NO · C6H8O7
Número CAS:
54965-24-1
Peso molecular:
563.64
Número MDL:
MFCD00058321
Código UNSPSC:
41116107
ID de substância PubChem:
329826577
NACRES:
NA.24

grau

pharmaceutical primary standard

família API

tamoxifen

fabricante/nome comercial

EDQM

técnica(s)

HPLC: suitable
gas chromatography (GC): suitable

aplicação(ões)

pharmaceutical (small molecule)

formato

neat

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

OC(=O)CC(O)(CC(O)=O)C(O)=O.CC\C(c1ccccc1)=C(/c2ccccc2)c3ccc(OCCN(C)C)cc3

InChI

1S/C26H29NO.C6H8O7/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3;7-3(8)1-6(13,5(11)12)2-4(9)10/h5-18H,4,19-20H2,1-3H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b26-25-;

chave InChI

FQZYTYWMLGAPFJ-OQKDUQJOSA-N

Informações sobre genes

human ... ESR1(2099)

Procurando produtos similares? Visita Guia de comparação de produtos

Categorias relacionadas

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Tamoxifen citrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Ações bioquímicas/fisiológicas

Protein kinase C inhibitor. Induces apoptosis in human malignant glioma cell lines. Tamoxifen and its metabolite 4-hydroxytamoxifen are selective estrogen response modifiers (SERMs) that act as estrogen antagonists in mammary gland. Blocks estradiol-stimulated VEGF production in breast tumor cells.

Embalagem

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Outras notas

Sales restrictions may apply.

Palavra indicadora

Danger

Classificações de perigo

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 1B - Repr. 1B

Código de classe de armazenamento

6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Lamentamos, não temos COA para este produto disponíveis online no momento.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 6

1 of 6

4-Hidroxitamoxifeno analytical standard, (E) and (Z) isomers (50:50)

Supelco

T176

4-Hidroxitamoxifeno

Estradiol meets USP testing specifications

Sigma-Aldrich

E1024

Estradiol

Doxorrubicina European Pharmacopoeia (EP) Reference Standard

D2975000

Doxorrubicina

Doxorrubicina British Pharmacopoeia (BP) Reference Standard

BP990

Doxorrubicina

Trichostatin A ≥98% (HPLC), from Streptomyces sp.

Sigma-Aldrich

T8552

Trichostatin A

cis-Diammineplatinum(II) dichloride crystalline

Sigma-Aldrich

P4394

cis-Diammineplatinum(II) dichloride

K I Pritchard
Journal of internal medicine, 274(2), 144-152 (2013-07-13)
Hormonal therapy for breast cancer is the first targeted therapy used in any type of cancer. It was used successfully without a known target for more than 50 years before Jensen described the oestrogen receptor (ER) in the 1960s. Subsequently, it
Kevin S Hughes et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(19), 2382-2387 (2013-05-22)
To determine whether there is a benefit to adjuvant radiation therapy after breast-conserving surgery and tamoxifen in women age ≥ 70 years with early-stage breast cancer. Between July 1994 and February 1999, 636 women (age ≥ 70 years) who had
P Fox et al.
British journal of cancer, 109(1), 147-153 (2013-06-20)
The host inflammatory response has a vital role in carcinogenesis and tumour progression. We examined the prognostic value of inflammatory markers (albumin, white-cell count and its components, and platelets) in pre-treated patients with advanced renal cell carcinoma (RCC). Using data
Esther Castellano et al.
Cancer cell, 24(5), 617-630 (2013-11-16)
RAS proteins directly activate PI3-kinases. Mice bearing a germline mutation in the RAS binding domain of the p110α subunit of PI3-kinse are resistant to the development of RAS-driven tumors. However, it is unknown whether interaction of RAS with PI3-kinase is
Matthew A Firth et al.
The Journal of experimental medicine, 210(13), 2981-2990 (2013-11-28)
Development of the natural killer (NK) cell lineage is dependent on the transcription factor Nfil3 (or E4BP4), which is thought to act downstream of IL-15 signaling. Nfil3-deficient mice lack NK cells, whereas other lymphocyte lineages (B, T, and NKT cells)
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica